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The association of increasing serum levels of fibrinogen products, coronary patency at 90 min after the start of 
degradation products after recombinant tissue-type plas- r&PA infusion was not better (13% less, 95% confidence 
minogen activator @t-PA) therapy with bleeding and early interval -33%, 13%) than in patients with low serum 
coronary patency was assessed in 242 patients with acute levels. This uncoupling of thrombolytic effect in terms of 
myocardial infarction. After administration of 5,000 III coronary patency and systemic fibrinogenolysis confirms 
heparin, a median of 40 mg (range 35 to 60) of double chain the experimentally demonstrated fibrin specificity of double 
H-PA was given intravenously in 90 min. Bleeding occurred chain r&PA in human subjects. Because fibrin specificity of 
in 62 patients; in 73% of patients it was observed within the single chain r&PA is at least similar to that of double chain 
1st 24 h and 84% of events consisted of hematoma or rtPA, the observations in this analysis most likely hold also 
prolonged bleeding, or both, at puncture sites. Bleeding for single chain r&PA. 
events occurred 2.12 times as ollen in patients with serum These findings suggest that a dose of r&PA just below 
levels of fibrinogen degradation products >85 mg/liter as in the threshold that causes systemic fibrinogenolysis might be 
patients with serum levels ~22 mg/Iiter (95% confidence optimal in terms of bleeding and coronary patency. Mea- 
interval 1.01 to 4.43). surements of fibrinogen degradation products during r&PA 
The infarct-related coronary vessel was patent in 65% of infusion might help to titrate &PA dosing in individual 
patients at 90 min after the start of r&PA infusion. In patients. 
patients with high serum levels of fibrin(ogen) degradation (J Am Co11 Cardiol1989;14:581-8) 
Recombinant human tissue-type plasminogen activator (rt- 
PA) has been shown in the Thrombolysis in Myocardial 
Infarction (TIM1 I) trial (1) to be twice as effective as 
intravenous administration of streptokinase to recanalize 
occluded infarct-related coronary arteries in patients with 
acute myocardial infarction and to yield more frequently 
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patent coronary arteries 90 min after the start of treatment 
(2). Furthermore, r&PA preserves left ventricular function 
(3,4) and reduces both enzymatic infarct size and mortality 
after myocardial infarction (3,5). 
It is a fibrin-specific thrombolytic agent: plasminogen is 
converted to plasmin primarily at the site of the thrombus. 
However, at high dosages used for treatment of acute 
myocardial infarction, this fibrin specificity is partly lost and 
fibrinogen breakdown in the circulation occurs in part of the 
patients (2,6). In patients treated with intracoronary strep- 
tokinase or urokinase, increasing systemic fibrinogenolysis 
is associated with more frequent recanalization (7,8). It is 
unknown whether this sequence is similar for patients 
treated with rt-PA. Furthermore, it is unknown to which 
degree fibrinogen degradation products developing after 
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administration of t-t-PA contribute to the occurrence of 
bleeding complications. 
In this analysis, the association of increasing serum levels 
of fibrinogen degradation products with bleeding and early 
coronary patency after &PA therapy in 242 patients with 
acute myocardial infarction is assessed. The influence of 
other known determinants of bleeding or coronary patency 
on this association (confounding) is eliminated by multivari- 
ate logistic regression analysis. 
Methods 
Patients and management. The present investigation is 
based on data from patients treated with r-t-PA in the first 
three trials of the European Co-operative Study Group for 
t-t-PA (2,9,10) in which the protocols and methods for data 
collection were similar. All protocols were approved by 
institutional committees on human research and for all three 
trials only patients who gave informed consent were eligible 
for participation. The first trial (9) was a double-blind and 
randomized comparison of coronary patency after &PA 
(0.75 mg r&PA/kg body weight intravenously over 90 min) 
with coronary patency after placebo in 129 patients from six 
centers. In the second trial (2), coronary patency after 0.75 
mg r&PA/kg body weight given intravenously over 90 min 
was compared with coronary patency after 1.5 million IU 
streptokinase given intravenously over 60 min in 129 patients 
from seven centers. In the third trial (lo), coronary patency 
and the influence of a second infusion of 30 mg rt-PA over 
6 h on subsequent reocclusion at 6 to 24 h was assessed in 
123 patients from 11 centers treated with 40 mg rt-PA over 90 
min. 
Patients between 21 and 70 years of age with ~30 min of 
chest pain and ST segment elevation of 20.3 mV in two or 
more electrocardiographic (ECG) precordial leads or ~0.2 
mV in two or more limb leads were eligible for inclusion, 
provided that rt-PA infusion could be started within 6 h from 
onset of symptoms in the first two trials and within 4 h in the 
third trial. In the first two trials, patients with a previous 
infarction were excluded, whereas a previous myocardial 
infarction in another territory did not disqualify the patient 
for the third study. Otherwise. exclusion criteria were iden- 
tical. 
All consenting patients were immediately registered at an 
independent telephone service and received treatment allo- 
cation from that service. After blood sampling for coagula- 
tion assays, an intravenous bolus of 5,000 IU heparin was 
given. Thereafter, an intravenous infusion of R-PA was 
given over 90 min. The same batch of primarily double chain 
rt-PA was used in all three studies (G-l 1021, manufactured 
by Genentech Inc. and supplied by Boehringer Ingelheim 
International GmbH). 
Coronary angiography. The first coronary angiogram of 
the infarct-related vessel was performed between 75 and 90 
min after the start of rt-PA infusion. In the patients of the 
third study, coronary angiography was repeated at 6 to 24 h. 
All coronary angiograms were centrally assessed by teams of 
three assessors, of whom two were always present to 
maintain consistency. The infarct-related segment was iden- 
tified on the basis of ECG and angiographic evidence. 
Patency was defined as complete distal filling of the infarct- 
related coronary artery, not through collateral vessels, 
within three cardiac cycles at the first adequate contrast 
injection. 
Bleeding events. The protocol required a detailed descrip- 
tion of all bleeding complications at the end of the r&PA 
infusion, after the first coronary angiogram and at discharge, 
including hematoma ~5 cm in diameter and prolonged 
bleeding of >30 min duration. 
Hemostasis variables. Blood samples were collected be- 
fore and at 60 and 90 min after the start of &PA infusion. 
Tubes for blood collection were provided containing 0.5 ml 
sodium citrate (final concentration 0.01 moliliter) and apro- 
tinin to counteract proteolysis by in vitro plasmin formation 
(final concentration 150 KIU/ml) for the determination of 
levels of fibrinogen, fibrinogen degradation products and 
activated partial thromboplastin time. Blood samples were 
centrifuged within 1 h and stored at -20°C. All bemostasis 
tests were performed centrally in the Central Coagulation 
Laboratory (Leuven). Methods of assessment have been 
described previously (11). The normal value for the plasma 
level of fibrinogen is 2 to 4 g/liter and for serum level of 
flbrin(ogen) degradation products is <8 mg/liter. 
Data analysis. Of the 251 patients allocated to rt-PA in 
the three European trials, 9 were excluded from this analy- 
sis: 2 did not receive the full dose of rt-PA, 6 had unassess- 
able 90 min angiograms, and 1 had bleeding that was 
noticed during r-t-PA infusion and therefore could not be 
related to the serum level of fibrinogen degradation products 
after rt-PA administration. The remaining 242 patients re- 
ceived the full dose of rt-PA and had assessable 90 min 
angiograms 
Because the exact start of bleeding complications is often 
difficult to assess, all bleeding events throughout the hospital 
phase were included in this analysis. Bleeding rate was 
defined as the percent of patients with at least one bleeding 
event. When more than one bleeding event was reported for 
a patient, the time of the first noticed event was used. 
Patency rate was defined as the percent of patients with a 
patent infarct-related artery on the angiogram at the end of 
the 90 min rt-PA infusion. 
Patients were grouped in three equally sized subgroups 
according to the serum level of fibrinogen degradation prod- 
ucts after rt-PA infusion. The chosen levels of fibrin(ogen) 
degradation products of 22 and 85 mg/liter are therefore 
arbitrary. Three groups were selected to enable assessment 
of trends in bleeding and coronary patency and because 
more groups would weaken strength of associations. Subse- 
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Table 1. Effect of r&PA Infusion on Hemostasis Variables in 242 Patients 
191 Trial 2nd Trial 3rd Trial Total 
in = 611 (n = 62) In = 119) (I? = 242)* 
rt-PA dosage (mg) 60 140.601 55 (3.F.60, 40 (40.40) 40 (35.60) 
Fibrinogen (g/liter) 
Before infusion 2.7 12.3 to 3.5) 2.4 (2.0 to 2.81 2.6 (2.3 to 2.9) 2.6 (2.2 2.9) io 
At 60 min 2.0 (I.7 to 2.5) 1.8 (1.3 to 2.21 2.3 (1.9 to 2.7) ?.I (1.7 2.6) to 
At 90 min I .4 (0.9 to 2 3) I 3 (0.9 to I.71 1.8 (I.2 to 2.21 I.5 (1.0 2.3 to 
Fibrinlogenl degradation products (mgilirer) 
Before infusion 5 (5 lo 7) 6 (5 to I?) 3 (2 to 1) s (3 to 51 
At 60 min 15 (8 to 341 20 (I? to 351 I4 19 to 27) 17 (9 to iI) 
At 90 min 38 (I4 to 1%) 40 (20 to 120) 36 (I5 to 901 38 (I7 to 1101 
Activated partial thromboplastin time (s) 
Before infusion 60 (51 to 70 61 (SO 10 73) 5X (5 I tO 86) 60 (51 tO 751 
At 60 min 102 (RI to 141) YY (73 to 151) 1% (105 to 180) 125 (85 to 180) 
At 90 min II2 (72 to 16.0 126 (96 10 1x0) 180 1145 to 1801 163 (98 to 1801 
*For fibrinogen and fibrinlogen) degradation products. the number of patients with assessable blood wmples 
before infwon. at 60 min and at 9U min. respectwely. was IYX. 2 I? and 210: for actwated partial rhromboplastin time. 
199. 212. 208. Continuous variable< are given a~ median wifh the 1st and 3rd quartile in parentheses rt-PA = 
recombmant tissue-type plasmmogen activator. 
quently. bleeding and patency rates were determined in each 
subgroup. The subgroup with low serum levels of fibrin- 
(ogen) degradation products was chosen as the reference 
group. The second and third subgroups were compared with 
the reference group with use of rate ratios (that is, the rate in 
the second or third group divided by the rate in reference 
group): 95% confidence intervals for rate ratio, were deter- 
mined according to the method of Katz et al. (12). 
Distortion in the relntion hetbveen sewn levels ofjihrin or 
jfihrinogen depxlution products and bleeding or patrncj 
fconfounding) caused by unequal distributions of other 
known determinants of bleeding or patency among these 
subgroups was simultaneously eliminated by multivariate 
logistic regression analysis. The following determinants of 
bleeding were considered: I) trial in which the patient 
participated, 2) age. 31 gender. 4) pulmonary rales before 
allocation, 5) thrombocyte count before rt-PA infusion. 6) 
fibrinogen after rt-PA, 7) activated partial thromboplastin 
time after rt-PA, reflecting mainly the degree of hepariniza- 
tion, 8) streptokinase given after rt-PA. and 9) second 
infusion of rt-PA in the third trial (IO). Similarly, for coro- 
nary patency, the determinants considered were: 1) trial in 
which the patient participated, 2) age, 3) gender. 4) use of 
intravenous nitrates, which has been reported to be benefi- 
cial for coronary patency in the setting of thrombolytic 
therapy (13.14). and 5) activated partial thromboplastin time. 
prolonged mainly by heparinization, which possibly im- 
proves thrombolytic efficacy (15,16). A detailed description 
of the design of the multivariate logistic regression models 
and methodology to obtain adjusted rate ratios and 95% 
confidence: intervals is given in the Appendix. 
Results 
Clinical features. The median age of the 242 patients was 
56 years (range 3 I to 70); 223 were male (84%). The median 
delay from the onset of symptoms to the start of rt-PA 
infusion was 2.8 h (range 0.9 to 5.8). A median dose of 40 mg 
(range 35 to 60) of rt-PA was administered over 90 min. Ten 
patients (4. I%) died during the hospital stay, 2 on the 1st day 
and 8 after the 4th day. No death was related to a bleeding 
complication. Cardiogenic shock was the cause of death in 
five patients, thromboembolism in 2. cardiac tamponade in 2 
and electromechanical dissociation during late angiography 
in I. 
Hemostasis variables before, during and after r&PA (Ta- 
ble 1). A moderate decrease in fibrinogen and a moderate 
increase in serum level of fibrin or fibrinogen degradation 
products were observed during rt-PA infusion. Before treat- 
ment. 1% of the patients (2 of 198 with analyzable blood 
samples) had a fibrinogen level <I g/liter and at 90 min 22% 
(46 of 210 with analyzable blood samples). At 90 min, a 
serum level of fibrin(ogen) degradation products ~22 mgi 
liter was found in 67% of the patients (I41 of 210 with 
assessable blood samples). The activated partial thrombo- 
plastin time was increasingly prolonged during rt-PA infu- 
sion. a finding that reflects the hepdrin administration and to 
a minute extent the formation of fibrin(ogen) degradation 
products. 
In the first two trials, the rt-PA dosage was higher than 
that in the third trial (Table I). This is reflected in a trend 
toward a lesser decrease in fibrinogen and lower serum 
levels of fibrin(ogen) degradation products at 90 min after 
start of rt-PA infusion in the third trial (IO). Nevertheless. 
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Table 2. Survey of the 62 Bleeding Events in All 242 Patients and 
the Time That the Bleeding Was First Noticed 
No. of Patients With 
Within 24 to 
24 h 48 h 
After 
48 h Total 
Retroperitoneal bleeding 
Hematemesis 
Hematuria 
Hematuria + gum bleeding 
Gum bleeding 
Hematuria + prolonged bleeding 
Hematoma and/or prolonged bleeding 
Blood transfusion given 
No blood transfusion given 
Unexplained anemia 
Total 
No. of patients with blood 
transfusion 
- I - I 
2 - - 2 
I - I 7 
I - - I 
2 - - 2 
- I I 
6 2 
33 7 
- - 
45 10 
- 6 
I 9 
3 43 
I I 
7 62 
4 IO 
the activated partial thromboplastin time was more pro- 
longed than that in the other trials, probably by more rigid 
heparinization in the third trial. 
Bleeding events (Table 2). In seven patients, two bleeding 
events were reported; the bleeding rate was 26% (62 of 242 
patients). Most bleeding complications occurred within the 
1st 24 h (73%) and consisted of hematoma or prolonged 
bleeding, or both, at a puncture site (84%). Two patients had 
hematemesis: one was treated with cimetidine, the other did 
not receive special therapy. Retroperitoneal bleeding was 
suspected in another patient with epigastric pain and de- 
crease in hemoglobin from 14.7 to 10.2 g/d]; no special 
treatment was given and the patient was discharged on the 
Table 3. Increasing Serum Levels of Fibrincogen) Degradation 
Products (mgiliter at 90 min) in Relation to Bleeding and Coronary 
Patencv Rate 
Fibrinfogenl Degradation 
Products at 90 min 
(mgiliter) 
Bleeding Rate 
Crude Rate 
Ratio 
Adjusted Rate 
Ratio 
<22 
22 to 85 
285 
Missing 
16% C 11169) 
29% 120169) 
38% 127172) 
13% (4132) 
Patency Rate 
Reference 
1.82 (0.94 to 3.50) 
2.35 (1.27 to 4.37) 
0.7X (0.27 to 2.28) 
Reference 
1.40 (0.73 to 2.65) 
2.12 (I.01 to 4.43) 
0.83 (0.27 to 2.5s) 
<22 
22 to 85 
Z85 
Missing 
70% (48169) 
58% (40169) 
64% (46172) 
75% (24/32) 
Reference 
0.83 (0.65 to 1.08) 
0.92 (0.73 to I .l6) 
I .08 (0.84 to I .39) 
Reference 
0.75 (0.57 to 0.99) 
0.87 (0.67 to 1.13) 
I. I3 (0.82 to I .56) 
Crude and adjusted rate ratio, respectively, before and after elimination of 
distortion of the relation between serum levels of fibrintogen) degradation 
products and bleeding or coronary patency caused by unequal distribution of 
other determinants of bleeding or coronary patency over the various catego- 
ries of serum levels of fibrincogen) degradation product (see Methods): 95% 
confidence intervals are presented in parentheses. 
1 I th day. No intracranial bleeding occurred. Blood transfu- 
sion was given to IO (16%) of 62 patients with a bleeding 
event: for hematoma in 7 patients, a combination of he- 
matoma and prolonged bleeding in 2 and unexplained anemia 
in 1 patient. No patient classified as a nonbleeder received 
blood transfusion. 
Fibrinogen degradation products and bleeding (Table 3). 
The bleeding rate was higher among patients with higher 
serum levels of fibrin(ogen) degradation products. Patients 
with a serum level of >85 mg/liter had a bleeding complica- 
tion approximately twice as often as did those with a serum 
level ~22 mgiliter. This relation was maintained after adjust- 
ment by multivariate logistic regression analysis. The varia- 
bles that were used for this adjustment are listed in the 
Appendix. The other variables mentioned in the Methods 
section did not influence the relation between serum levels of 
fibrin(ogen) degradation products and bleeding. Figure 1 
depicts the relation between serum levels of fibrinogen 
degradation products and bleeding, adjusted for the varia- 
bles listed in the Appendix, together with its 95% confidence 
range. 
Coronary patency. At 90 min after the start of rt-PA 
infusion, the infarct-related vessel was found patent in 159 of 
the 242 patients (patency rate 6.5%, 95% confidence interval 
59 to 71). The patency rate was similar in the three trials: 
61% (95% confidence interval 48 to 73) in the first trial, 69% 
(95% confidence interval 56 to 80) in the second trial and 66% 
(95% confidence interval 56 to 74) in the third trial. 
Fibrin or fibrinogen degradation products and patency 
(Table 3). A trend of decreasing coronary patency was 
observed with increasing serum levels of fibrinogen degra- 
dation products before and after correction by logistic anal- 
ysis. The variables used in the logistic regression model are 
given in the Appendix. The other determinants of coronary 
patency mentioned in the Methods section did not distort the 
relation between fibrin(ogen) degradation products and cor- 
onary patency. Figure 2 illustrates the absence of higher 
patency rates with increasing serum levels of fibrinogen 
degradation products. 
Discussion 
Recombinant tissue-type plasminogen activator (rt-PA) is 
an effective thrombolytic agent with limited systemic fibrino- 
genolysis in the vast majority of patients, when compared 
with intravenous streptokinase. However, bleeding ha, re- 
mained a frequent side effect in the clinical trials so far 
(1.2.3.6). This analysis reveals that increasing serum levels 
of fibrinogen degradation products are related to more 
frequent bleeding complications, but not to greater coronary 
patency at 90 min after the start of rt-PA infusion. 
Fibrinogen degradation products and bleeding. The rela- 
tion between fibrin(ogen) degradation products and bleeding 
might be explained by the fact that fibrinogen degradation 
JACC Vol. 14, No. 3 
September 1989:581-8 
ARNOLD ET AL. 585 
FIBRINOGEN DEGRADATION PRODUCTS AFTER RT-PA. BLEEDING AND CORONARY PATENCY 
Figure 1. Bleeding rate as a function of increasing serum levels of 
fibrin(ogen) degradation products (as continuous variable, logarith- 
mic scale) at 90 min after start of r&PA infusion. Confounding by 
other determinants of bleeding was eliminated by multiple logistic 
regression analysis. The dotted lines represent 95% confidence 
limits. &PA = recombinant tissue-type plasminogen activator. 
products act as antithrombins, fragment Y being the most 
active (18). There is evidence that fibrinogen degradation 
after r&PA results in relatively large amounts of early 
degradation products belonging to the fragment X and Y 
groups (11). In addition, fibrinogen degradation products 
inhibit fibrin polymerization, resulting in a defective fibrin 
structure, and impair platelet function (18). Also, the TIMI 
study group reported a relation between serum levels of 
fibrinogen degradation products and bleeding after adminis- 
tration of double and single chain rt-PA (6). However, in that 
report no adjustment for confounding variables was made by 
multivariate regression analysis. 
The adjusted rate ratios of 1.40 and 2.12 for bleeding at 
increasing levels of fibrinogen degradation products are 
probably an underestimation of the strength of the relation 
Figure 2. Coronary patency rate as a function of increasing serum 
levels of fibrinogen degradation products (as continuous variable, 
logarithmic scale) at 90 min after infusion of rt-PA. Confounding by 
other determinants of coronary patency was eliminated by multiple 
logistic regression analysis. The dotted lines represent 95% confi- 
dence limits. rt-PA = recombinant tissue-type plasminogen 
activator. 
because they are conditional on the prolongation of activated 
partial thromboplastin time, which is partly caused by fibrin- 
ogen degradation products. 
Fibrinogen degradation products and patency. Increasing 
serum levels of fibrin(ogen) degradation products were not 
related to better coronary patency at 90 min, but tended to 
be inversely related to coronary patency. The TIM1 study 
group (19) also reported an inverse relation between sys- 
temic fibrinogenolysis and recanalization at 90 min for 
double chain rt-PA; patients with recanalization had 31% 
decline in fibrinogen versus 41% in those patients without 
recanalization (95% confidence interval for this 10% differ- 
ence: 8% to 12%). The possibility of an inverse relation is 
worth further investigation, both in vitro and in animal and 
clinical studies. An explanation could be that systemic 
fibrinogenolysis counteracts the fibrinolytic efficacy of CPA 
through negative feedback (inactivation of t-PA by fibrin- 
ogen degradation products?). 
In patients treated with streptokinase or urokinase, reca- 
nalization occurs more frequently with increasing serum 
levels of fibrinogen degradation products (7,8). This finding 
is in agreement with the fact that streptokinase and uroki- 
nase are not fibrin specific and result in conversion of 
plasminogen to plasmin in the free circulation, producing 
breakdown of fibrinogen and clotting factors V and VIII (18). 
It could be argued that prolongation of activated partial 
thromplastin time might not be a determinant of coronary 
patency, because the Thrombolysis and Angioplasty in Myo- 
cardial Infarction (TAMI) study group (20) recently reported 
that patients given heparin concomitant with rt-PA did not 
have a higher coronary patency rate than did patients given 
rt-PA alone. Also, it has been suggested (21) that heparin 
might reduce plasmin formation by t-PA at the site of the 
thrombus. Therefore, the multivariate logistic regression 
analysis in this analysis was repeated without activated 
partial thromboplastin time. The same trend was found for 
the relation between serum levels of fibrinogen degradation 
products and coronary patency, although less pronounced 
(rate ratio and 95% confidence interval for serum level of 
fibrinogen degradation products from 22 to 85 mg/liter, 0.82; 
0.63 to 1.06; for serum level of fibrinogen degradation 
products 285 mgiliter, 0.92, 0.72 to 1.18). 
Limitations of the analysis. The test developed by Mers- 
key that we used in these studies does not differentiate 
between fibrin degradation and fibrinogen degradation prod- 
ucts. However, this lack does not invalidate our analysis 
because the degradation products after thrombolysis with 
rt-PA for acute myocardial infarction consist primarily of 
fibrinogen degradation products (22). Similarly, in pulmo- 
nary embolism where fibrin mass is much larger than that in 
coronary thrombosis, predominantly fibrinogen degradation 
products were found (23). Therefore, in the present analysis 
the degradation products observed most likely reflect fibrin- 
ogen degradation and not fibrin degradation. 
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Another concern could be that in vitro degradation of 
fibrinogen might have occurred between blood collection 
and deep-freezing, which is not completely eliminated by 
aprotinin. If indeed fibrinogen degradation products in the 
present analysis originated mainly from in vitro degradation, 
the serum level of such products reflects lytic activity in 
serum rather than in vivo fibrinogen breakdown. Greater 
lytic activity in serum would then be associated with in- 
creased bleeding rate, but not with higher coronary patency. 
One should be cautious in extrapolating the relation 
between fibrinogen degradation products and bleeding 
events that was observed in the present analysis to other 
forms of bleeding (e.g., intracranial bleeding). In this inves- 
tigation, the incidence of serious bleeding events was too 
low to allow separate analyses of various types of bleeding. 
Finally, it should be appreciated that in all patients in these 
trials acute angiography was performed to assess coronary 
patency. One would expect less frequent bleeding if acute 
catheterization is not performed. However, in patients 
treated with rt-PA without acute angiography, similar inci- 
dence rates ranging from 23% to 29% and similar types of 
bleeding have been reported (3,24). 
Implications of the present analysis. Increasing serum 
levels or fibrinogen degradation products were related to 
more frequent bleeding, but not to better coronary patency. 
The observation that thrombolytic effect and systemic fibrin- 
ogenolysis were completely uncoupled confirms the fibrin 
specificity of double chain rt-PA in patients. These findings 
probably hold also for single chain r--PA because fibrin 
specificity of single chain rt-PA is at least similar to fibrin 
specificity of double chain rt-PA. Although single chain 
rt-PA needs to be administered at higher doses than does 
double chain rt-PA. because of its shorter plasma half-life, it 
resulted in less fibrinogen breakdown at equipotent doses in 
terms of coronary recanalization (6). 
These considerations suggest that there may be an opti- 
mal dose of rt-PA for every individual with maximal throm- 
bolytic effect and without fibrinogen breakdown, whereas at 
higher doses, systemic fibrinogenolysis is induced with an 
increased risk for bleeding but without better thrombolytic 
effect. Determination of fibrinogen degradation product lev- 
els during r&PA infusion might help to identify this optimal 
dose for an individual patient. Rapid tests for quantitative or 
semiquantitative determination of levels of fibrinogen degra- 
dation products, preferrably in whole blood and specifically 
measuring fibrinogen degradation products, should be devel- 
oped. These tests might enable the clinician to titrate the 
rt-PA dosage, in a manner similarly to the titration of insulin 
dosage on the basis of blood sugar levels. This approach, 
which is restricted to fibrin-specific thrombolytic agents, 
might be even more relevant for possible indications as 
pulmonary lung embolism, artificial heart valve thrombosis 
and venous thrombosis, where time is less crucial than that 
in acute myocardial infarction. In addition, prolonged rt-PA 
infusion for prevention of coronary reocclusion after throm- 
bolysis for acute myocardial infarction might be individual- 
ized in this manner. 
Appendix 
Multivariate lo&tic regression analysis. Multiple logistic regres- 
sion analysis was performed with the BMDP statistical package 
(program LR). The relation between serum levels of fibrinogen 
degradation products and bleeding or patency was expressed in a 
multivariate logistic regression model. A set of reported variables 
that were known to be predictors of bleeding or patency was 
selected. These variables were forced in a model, one at a time, 
together with the various categories of serum levels of fibrin(ogen) 
degradation products. Only those variables affecting the relation 
Table 4. Multivariate Logistic Regression Model for the 
Assessment of the Relation Between Serum Levels of 
Fibrinfogen) Degradation Products and Bleeding 
Variable (X, ,I Bleeding Rate Coefficient (b,,) Standard Error 
Fibrintogen) Degradation Products (mg/liter) at 90 min 
C22 16% (11169) Reference - 
22 to 85 29% (20!69) 0.47 0.46 
~85 38% (27!72) 1.10 0.55 
Missing 13% 14132) -0.25 0.77 
Pulmonary Rales Before Allocation 
No 22% (431194) Reference 
Yea 40% (19/48) 0.90 0.39 
Thrombocytes Before Infusion (lO%ter) 
<?20 
220 to 280 
2280 
Missing 
39% (26:74l 1.13 
234 115;711 0.31 
19% Illi71) Reference 
39% (10:26) 1.35 
Fibrinogen al 90 mm (g/liter) 
0.45 
0.47 
- 
0.57 
Cl.21 31% (22/70) -0.40 0.56 
1.21 to 1.91 24% (18i74) -0.35 0.44 
21.91 27% t 18i66) Keference - 
Missing 13% (4132) -0.25 0.77 
aPTT at 90 min (F) 
C95 
95 10 1x0 
2180 
Missmg 
16% (8149) Reference 
24% (I%631 0.41 
37% (35196) 0.77 
12% (4!34) -0.25 
Second Infusion of 30 mg rt-PA (3rd trial) 
0.52 
0.49 
0.77 
NO 24% (471200) Reference 
Yes 36% (I 5142) 0.54 0.42 
Intercept -2.74 0.61 
aPTT = activated partial thromboplastin time (s): rt-PA = recombinant 
tissue-type plasminogen activator. 
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Table 5. Multivariate Logistic Regression Model for Assessment 
of the Relation Between Serum Levels of Fibrin(ogen) 
Degradation Products and Coronary Patency 
Variable (X,,) Patency Rate Coefficient lb,,) Standard Error 
Fibrinfogen) Degradation Products (mgiliterl at 90 min 
42 70% t48i69l Reference 
22 to 85 58% (40169) -0.76 0.38 
2x5 64% 146/721 -0.39 0.37 
Missing 75% (243321 0.39 0.54 
Nitroglycerin iv 
NV 62% (106~1701 Reference 
Yes 72% 152172) 0.58 u.32 
aPTT at 90 min (s) 
<95 
95 to 180 
2180 
Missing 
SYSh 09i49) Reference 
56% (35/63) -0.24 
7 I R (68i96) 0.62 
77% t26/34) 0.39 
- 
0.39 
U.38 
0.54 
Intercept 0.59 
iv = intravenous: other abbreviations as in Table 4. 
0.35 
between the various categories of these serum levels and bleeding or 
patency were combined in a final model. Adjusted rate ratios and 
9% confidence intervals for the various categories of serum levels 
of fibrinogen degradation products were obtained according to the 
method of Miettinen (17) by the following formula, in which the 
mean was entered for all variables (Xi) other than the category of 
serum levels of fibrinogen degradation products for which the 
adjusted rate ratio was determined: one for the category of serum 
level of fibrinogen degradation products under study (variable X.,J in 
the numerator and 0 in the denominator: 
Rate ratio = [I texp(-(intercept+C,b,X,th,*l))l-’ 
[l+exp(-(intercept t ZibiXitbi*O))]-’ 
95% confidence interval: rate ratio”-‘.Mh/ch’-“‘. rate ratio” + ’ ‘h’ch’-“‘: 
where chi.0 is the ratio of the fitted coefficient for the category of 
serum level of fibrinogen degradation products of which the confi- 
dence interval has to be determined, to the standard error (SE) of 
this coefficient. Coefficients ib,. b,] and standard errors for all 
variables in the final model are listed in Tables 4 and 5. 
We gratefully acknowledge the methodological advice of Jan G. P. Tbssen. 
PhD of the Clinical Epidemiology Unit of the Thoraxcenter and PatrIck 
Bossuyt. MSC of the Center for Clinical Declslon Analysis of the Erasmus 
University. Rotterdam. The Netherlands. 
References 
Chesebro JH. Knatterud G. Roberts R. et al. Thrombolysrs in Myocardlal 
Infarction (TLMI) Trial. phase I: a comparison between intravenous tissue 
plasmmogen actirator and intravenous ctreptokinase. Circulation 1987: 
76,142-54. 
Verstraete M, Bernard R. Bory M, et al. Randomised trial of mtravenous 
3 
4 
5 
6 
7 
8 
9 
IO 
II 
12 
13 
I4 
15. 
16. 
17. 
IR. 
I9 
20 
recombinant tissue-type plasminogen activator versus intravenous strep- 
tokinase in acute myocardial infarction. Lancet lY85;1:842-7. 
Van de Werf F. Arnold AER. for the European Co-operative Study Group 
for rt-PA. Effect of Intravenous tlssuc plasminogen activator on infarct 
$Ize. left ventricular function and survival in patrents with acute myocar- 
dial infarction. Br Med .I 1988:297: 1374-9. 
National Heart Foundation of .Australia. Coronary thrombolysis and 
myocardial salvage by ttsque plasminogen activator given up to 4 hours 
after onset of myocardial infarction. Lancet 1988:1:203-7. 
Wilcox RG. van der Lippe G. Olsson CC. et al. Trial of tissue plasmino- 
gen activator for mortality reduction in acute myocardial infarction 
(ASSET). Lancet 1988:ii:5?5-30. 
Mueller HS. Rao AK. Forman SA. et al. Thrombolysis in Myocardial 
Infarction (TIMI): comparative studies of coronary reperfusion and 
ayalemic fibrinogenolyaia with two forms of recombinant tissue-type 
plasminogrn activator. J Am Coil Cardiol 1987;10:479-90. 
Rothbard RL. Fltrpatrick PG. Francis CW. Calon DM, Hood WB, 
Marder VJ. Relationship of the lytic state to successful reperfusion with 
standard- and low-dose intracoronary streptokinase. Circulation 198b: 
71:56?-70. 
Burket MW. Smith MR. Walsh TE. Brewster PS. Fraker TD. Relation of 
effectivenesFofintracoronary thrombolysis in acute myocardial infarction 
to systemic thrombolytic state. Am J Cardiol 198S:S6:441-4. 
Verstraete hl, Blcifeld W. Brewer RW, et al. Double-blind. randomised 
trial of Intravenous tissue-type plasminogen activator versus placebo in 
acute myocardial infarction. Lancet 1985:2:965-9. 
Verstraete M. Arnold AER. Bleifeld W. et al. Acute coronary thrombol- 
ysis with recombinant human tissue-type plasminogen activator: initial 
patency and influence of maintained infusion on occlusion rdle. Am J 
Cardiol 1987:60:231-7. 
Collen D. Bounameaux H. De Cuck F. Lijnen HR. Verbtraete M. 
,Analysis of coagulation and tibrinolysis during intravenous infusion of 
recombinant human tissue-type plasmmogen activator in patients with 
acute myocardial infarction. Circulation 1986:73:51 l-7. 
Katz D, Beptlsta J. Azen SP. Obtaining confidence Intervals for the risk 
m cohort studies. Biometrics 1978:34,469-74 
Hackett D. Davies G, Chierchia S. et al. lntermlttent coronary occlusion 
m dcute myocardial infarction: value of combined thrombolytic and 
vaqodilator therapy. N Engl J Med 1987:317:1055-9. 
Rentrop KP. Feit F, Blanke H. et al. Effects of intracoronary streptoki- 
nase and intracoronary nitroglycerin infusion on coronary angiographic 
patterns and mortality in patients with acute myocardial infarction. 
N Engl J Med 1984:311:1457-63. 
Cercek B. Lew AS, Hod H. Enhancement of thrombolysis with tissue- 
type plasmmogen activator by pre-lreatment with heparin. Circulation 
1986:74:583-7. 
Paquer EP. Stoehr HA, Heimburger N. Study on the mechanism of actIon 
of heparin and related substances on the fibnnolytic system’ relation 
between plasminogen activators and heparm Thromb Res 1986:42:797- 
807. 
Miettinen OS. Theoretical Epidemiology: Prmciplcs of Occurrence Re- 
starch in Medicine. New York: John Wiley & Sons, 1985:235. 
Wintrohe MM. Lee GR. Bogs DR. et al. Clinical Hematology. 8th ed. 
Philadelphia: Lea 8i Febiger. 1981:434. 
Rao AK. Pralt C. Berke A, et al. Thrombolysis in Myocardial Infarction 
(TIMI) Trial-phase I: Hemorrhagic manifestations and changes in 
plasma fibrinogen and the fibrinolytic system in patients treated with 
r+PA and streptokinase. .I Am Coil Cardiol 1988;ll:I-Il. 
Top01 EJ. George BS. Kereiakes DJ. et al. A randomized controlled trial 
of intravenous tissue plasminogen activator and early intravenous heparin 
in acute myocardial infarction. Circulation 1989;79:281-6. 
588 ARNOLD ET AL. JACC Vol. 14. No. 3 
FIBRINOGEN DEGRADATION PRODUCTS .AFTER RT-PA. BLEEDING AND CORONARY PATEtiCY September 198’+581-8 
21. Andrade-Garden P. Stickland S. Interaction of heparin wth plasminogen 
activators and plasminogen: effects on the activation of plasminogen. 
Bioch 198h:25:4033-40. 
22. Declerck P. Mombaerts P. Holvoet P. Collen D. Plasma levels of 
fragment D-dimer of cross-linked fibrin during thrombolytic therapy with 
recombinant tissue-type plasminogen activator (abstrl. Thromb Haemost 
1987:58:231. 
23. Goldhaher SZ. Kessler CM. Hiet J. et al. Randomiwd controlled trial of 
recombinant tissue plasminogen activator verwq urokinase in the treat- 
ment of acute pulmonary embolism. Lancer 1988;2:293-8. 
24. Simoons ML. Arnold AER. Betriu A. et al. Thrombolysis with tissue 
plasminogen activator in acute myocardial infarction: no additional ben- 
elit from immediate percutaneous coronary angioplasty. Lancet 1988: 
1:197-204. 
